MedPath

Clinical trial of evaluation of Methimazole 5% cream effectiveness versus Hydroquinone cream 2% to reduce pregnancy spots (melasma)

Phase 2
Conditions
melasma.
Chloasma
Registration Number
IRCT2016073129145N1
Lead Sponsor
Vice chancellor for research, Iran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Ages from 18 to 50; Normal to dry skin; without comedones
Exclusion criteria: Absence of follow up by patients and not satisfied to continue; Complications such as allergy to topical agent; Pregnancy and lactation; Thyroid disease; Oral contraceptive pills use and other drugs that cause melasma.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Hyperpigmentation of face skin. Timepoint: At first and 8 weeks after treatment. Method of measurement: Intensity of the darkening of the face skin compared to other areas of the face with visioface device.
Secondary Outcome Measures
NameTimeMethod
Satisfaction amount. Timepoint: After completion of treatment. Method of measurement: Comparison of reduction hyperpigmentation by patient, before and after treatment According to schedule.
© Copyright 2025. All Rights Reserved by MedPath